These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29736895)

  • 21. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC; Mauskopf J; Borker R
    Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
    Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
    J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of omalizumab on medical cost of childhood asthma in Japan.
    Yoshikawa H; Iwata M; Matsuzaki H; Ono R; Murakami Y; Taba N; Honjo S; Motomura C; Odajima H
    Pediatr Int; 2016 May; 58(5):425-8. PubMed ID: 27173421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD.
    Einarson TR; Bereza BG; Nielsen TA; Van Laer J; Hemels ME
    J Med Econ; 2016; 19(4):319-55. PubMed ID: 26535917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
    Hernandez L; O'Donnell M; Postma M
    Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
    van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
    J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?
    Dilokthornsakul P; Chaiyakunapruk N; Campbell JD
    J Asthma; 2017 Jan; 54(1):17-23. PubMed ID: 27284904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
    Navarro RP; Parasuraman B
    Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials.
    Corren J; Kavati A; Ortiz B; Vegesna A; Colby JA; Ruiz K; Panettieri RA
    Curr Med Res Opin; 2018 Jan; 34(1):65-80. PubMed ID: 29057669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab.
    Shaker M; Briggs A; Dbouk A; Dutille E; Oppenheimer J; Greenhawt M
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):565-572. PubMed ID: 31626991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.